Biotech Values

[DewDiligence]

GSK/THRX—Relvar/Breo* Ellipta fails to show statsig survival benefit in COPD phase-4 study:

http://finance.yahoo.com/news/gsk-theravance-announce-results-summit-184000004.html

For the primary endpoint of the study, the risk of dying on FF/VI 100/25mcg [i.e. Relvar/Breo combination] was 12.2% lower than on placebo over the study period, which was not statistically significant (p=0.137).

THRX is down 22% on this news.

*Relvar and Breo are two brand names for the same ICS/LABA combination product. Ellipta is the brand name for the inhalation device.